Från professionella översättare, företag, webbsidor och fritt tillgängliga översättningsdatabaser.
it may be asymptomatic and responds to treatment with thyroxine and resolves upon withdrawal of treatment.
den kan være asymptomatisk og reagerer på behandling med thyroxin.den svinder, når lægemidlet ikke længere indtages.
reduced serum thyroxine led to an increased release of tsh with resultant follicular cell hypertrophy in the thyroid glands of rats.
nedsat serum thyroxin forårsagede en stigning i frigivelse af tsh med efterfølgende follikulær celle hypertrofi i skjoldbruskkirtlerne hos rotter.
in addition l-dopa, l-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β2 sympathomimetics.
desuden kan l-dopa, l-thyroxin, oxytocin og alkohol svække hjertets tolerance over for β2-adrenerge sympatomimetika.
common: adrenal insufficiency, decreased free thyroxine, decreased free tri-iodothyronine, increased blood tsh, hypothyroidism
almindelig: binyreinsufficiens, nedsat frit thyroxin, nedsat frit triiodothyronin, øget tsh i blodet, hypothyroidisme*
transient falls in thyroxine (t4) have been recorded in infants at the start of therapy but these are not sustained with maintained therapy.
der er registreret forbigående fald i thyroxin (t4) hos spædbørn i starten af behandlingen, men de opretholdes ikke i forbindelse med vedvarende behandling.
in rats, at similar exposure levels, an increased incidence of thyroid adenomas was seen, probably related to an increase in release of thyroid stimulating hormone secondary to an increase in thyroxine clearance.
ved lignende eksposition hos rotter sås en øget forekomst af thyroide adenomer, sandsynligvis relateret til en stigning i frigørelsen af thyroideastimulerende hormon sekundært til en stigning i thyroxinclearance.
the adverse reactions most commonly reported were injection site related reactions, peripheral oedema, headache, myalgia, arthralgia, paraesthesia, hypothyroidism and decreased free thyroxine.
de mest almindelige bivirkninger var reaktioner på injektionsstedet, perifert ødem, hovedpine, myalgi, artralgi, paræstesi, hypothyroidisme og nedsat frit thyroxin.
an increase in thyroidal weight and thyroidal follicular cell hyperplasia, due to an increase in thyroxine clearance, was seen in rats treated with indinavir at doses 160 mg/kg/day.
forhøjet thyroideavægt og thyroidal follikelcellehyperplasi som følge af forhøjet thyroxinclearance sås hos rotter behandlet med indinavir i doser 160 mg/kg/dag.
in clinical trials, no interactions were observed between thyrogen and the thyroid hormones triiodothyronine (t3) and thyroxine (t4) when administered concurrently.
der konstateredes ingen interaktioner mellem thyrogen og thyreoideahormonerne triiodothyronin (t3) og thyroxin (t4) ved kliniske forsøg, når de blev indgivet samtidigt.
raloxifene modestly increases hormone-binding globulin concentrations, including sex steroid binding globulins (shbg), thyroxine binding globulin (tbg), and corticosteroid binding globulin (cbg), with corresponding increases in total hormone concentrations.
raloxifen øger i beskedent omfang koncentrationerne af hormonbindende globulin, inklusiv køns- hormonbindende globuliner (shbg), thyroxinbindende globulin (tbg) og kortikosteroidbindende globulin (cbg) med tilsvarende stigninger i totale hormonkoncentrationer.